Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. The liposomal formulation of PGE-1 changes... The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.
- Mechanism
- Curator reviewed
The encapsulated formulation (Liprostin) has been shown to improve the therapeutic index of PGE-1, positively impacting many areas of treatment, such as heart attacks, occlusive disease, ischemic ulcers, critical limb salvage, claudicants, and arthritis.
- Primary indication
- Investigated for use/treatment in neuropathy (diabetic) and peripheral vascular disease.Curator reviewed
- Also known as
- TLC C-53
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Liposomal prostaglandin E1, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account